| P/E (FY) | — | Sales (TTM) | €4.07B |
| Earnings (TTM) | €397.5M | ROE | 9.57% |
| Net Margin | 9.77% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 4.28% |
bioMerieux develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases across France, Europe, Africa, the Middle East, the Americas, Asia Pacific, and internationally, through Clinical Applications and Industrial Applications segments. Its products include CHROMID culture media, air, surface, and water monitoring systems, the BACT/ALERT VIRTUO blood culture system, BIOFIRE PCR systems, VITEK identification and antimicrobial susceptibility testing systems, ETEST, and the VIDAS immunoassay platform.
| Market Cap | $103.6M | Trading Days | 4173 |
| 52W High | 128.30 |
| 52W Low | 65.60 |
| % Off High | −44.89% |
| YTD | −35.02% | 1Y | −42.57% |
| 3Y | −26.60% | 5Y | −22.03% |
| 10Y | 84.15% | Since incept. (ann.) | 6.76% |
| Ann. Volatility (1Y) | 29.82% | Ann. Volatility (3Y) | 25.52% |
| Sharpe (1Y) | −1.81 | Sharpe (3Y) | −0.27 |
| Max Drawdown (1Y) | −47.38% | Max Drawdown (3Y) | −47.38% |
| Beta (3Y, vs SPY) | −0.05 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| OGI | ORGANIGRAM GLOBAL INC. | $103.0M | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $102.0M | — |
| IXHL | Incannex Healthcare Inc. | $102.0M | — |
| ICCC | IMMUCELL CORP /DE/ | $101.7M | — |
| LAKE | LAKELAND INDUSTRIES INC | $105.9M | — |
| BDTX | Black Diamond Therapeutics, Inc. | $100.9M | 4.5 |
| TCRX | TScan Therapeutics, Inc. | $100.4M | — |
| AZT.OL | ARCTICZYMES TECHNOLOGIES ASA | $100.4M | 115.9 |
| GBT.PA | GUERBET | $107.0M | — |
| XGN | EXAGEN INC. | $107.5M | — |
| OTLK | Outlook Therapeutics, Inc. | $109.3M |
| SERA | SERA PROGNOSTICS, INC. | $96.8M | — |
